Overall, our data support the notion that small molecule-mediated RET G4 stabilization may represent a valid molecular approach for the therapeutic regulation of RET signaling in MTC and contribute to furnish the biological rationale for future development of novel G4 stabilizing-based treatment options for MTC or other neoplastic diseases, such as breast cancers [36] and neuroblastoma [37] for which RET may represent a suitable therapeutic target. The gene discussed is RET; the disease is breast cancer.